IM8 sells a subscription wellness drink designed to replace a messy stack of daily supplements with one routine. The IM8 funding news is huge: General Catalyst’s Customer Value Fund has committed up to $1 billion to the David Beckham-backed startup without taking an equity stake, which is rare even by startup-finance standards. That matters because consumer health brands usually burn a lot of cash chasing customers, and dilution is often the price of that growth. IM8 launched in 2024 with entrepreneur Danny Yeung and Beckham, and the company now has a financing tool built for aggressive acquisition rather than traditional venture optics.
This isn’t a normal VC round. It’s basically a bet on repeat purchases.
What is IM8 and how does it work?
IM8 is a consumer wellness brand that sells a daily drink mix on subscription. The idea is simple: instead of buying separate vitamins, probiotics, and other add-ons one by one, customers sign up online and get recurring shipments. They use one product as a daily routine.
That’s the real product hook. Convenience first. Science-flavored branding second.
The drink itself is pitched around longevity and broad nutritional coverage. It bundles ingredients such as açai fruit extract and Coenzyme Q10 into a single formula. It aims at buyers who want an “all-in-one” health habit rather than a cupboard full of pill bottles. In practice, IM8 is selling simplification as much as supplementation.
Before products like this, the usual customer experience was fragmented. One bottle for multivitamins. Another for gut health. Something else for energy or recovery. IM8 turns that into one recurring purchase and one daily ritual, which is why subscription economics matter so much here — the company isn’t trying to win a one-off sale at retail.
That’s also why General Catalyst’s structure fits. If a brand can reliably turn marketing spend into long-term subscription revenue, financing customer acquisition starts to look less like pure risk and more like math.
What does IM8 funding tell us about the founders?
From Prenetics to a Beckham partnership
IM8’s operating brain is CEO Danny Yeung, a founder who has been around consumer health long enough to understand both hype and execution. He has described himself as a high-school dropout, which startup profiles love, but the more relevant point is his track record: he previously built Prenetics, a health company that went public in 2022.
IM8 sits inside that wider corporate orbit. It’s a subsidiary of Prenetics, not an isolated celebrity side project.
The founding story is unusually blunt. Yeung moved in the sort of circles that led to dinner with David Beckham, and that meeting helped turn a relationship into a business. Plenty of celebrity wellness brands are basically marketing shells. IM8 at least has a real operator behind it. It also has a public-company parent with experience in health products.
Why Yeung had a shot at building this
Yeung’s edge isn’t that he invented supplements. He didn’t. His edge is that he understands how to package health into something consumers will actually buy.
That matters more than people admit. Wellness is crowded and expensive. It’s also brutally dependent on trust. A founder who has already taken a health company public brings a different level of credibility than a random first-time consumer founder with a famous face on the box.
Beckham’s role matters too, but differently. He brings reach and instant recognition in a category where customer acquisition is half the battle. Yeung brings operating history. That combo is the real pitch.
Past execution is the story here
Prenetics going public in 2022 is the most important signal in Yeung’s résumé because it shows he’s already built something large enough to matter in public markets. That doesn’t guarantee IM8 works. Not even close. But it does mean investors aren’t backing a blank résumé.
General Catalyst didn’t structure this as a vanity endorsement deal. It backed a model tied to customer revenue.
Fundraising details that actually matter
The headline number is up to $1 billion from General Catalyst’s Customer Value Fund, or CVF. That pool doesn’t buy equity the way a standard venture round does. Instead, it provides capital that works more like a loan tied to future performance.
In IM8’s case, the facility is set up to cover as much as 70% of customer acquisition costs. In return, General Catalyst gets a capped share of what it calls reference income — revenue from those customers adjusted by a fixed gross-margin assumption. Once the firm gets its money back and reaches that cap, the remaining revenue from those customers flows back to Prenetics.
So, no new stock issued. No ownership stake for General Catalyst. No dilution for existing shareholders.
That’s the clever part. It lets IM8 spend big on growth without giving away more of the company.
Where IM8 sits against competitors
IM8 isn’t entering an empty category. It’s stepping into a premium supplements market already crowded with greens powders, daily drink mixes, vitamin packs, and subscription-led wellness brands. The obvious direct competition comes from all-in-one daily nutrition products like AG1, plus a long tail of functional wellness blends that sell convenience, energy, gut support, or healthy-aging benefits.
The legacy alternative is even bigger than those brands. It’s the old-school supplement cabinet.
That’s where IM8 tries to separate itself. It has celebrity distribution power through Beckham and a cleaner single-product pitch than many broad supplement catalogs. It also has a parent company with real health-business experience. General Catalyst is backing the part investors care about most: a predictable subscription engine that can justify heavy customer acquisition spend.
Why does the IM8 funding structure matter?
Here’s the blunt version: this deal is really about buying growth without selling ownership.
Consumer brands love recurring revenue, but they hate the cost of getting new customers. Ads are expensive. Influencer marketing is expensive. Retail expansion is expensive. Even strong brands can end up raising equity just to keep feeding that machine. IM8 now has a financing structure built specifically for that problem.
For customers, that could mean faster brand expansion and more aggressive marketing rather than immediate product reinvention. For the company, it means more room to scale before facing the usual “grow slower or dilute more” tradeoff.
General Catalyst’s thesis is pretty clear. CVF works best when a startup has predictable revenue streams and knows how extra capital converts into growth. IM8 fits that logic because subscriptions create a cleaner payback model than one-time consumer purchases.
And there’s precedent. Grammarly took the same kind of $1 billion financing from General Catalyst’s CVF in May 2025, shortly before buying Superhuman. That deal helped normalize the idea that not every large startup check has to come through equity.
How big is the market behind IM8 funding?
The market IM8 is chasing is already massive. The global dietary supplements sector was valued at roughly $177 billion in 2023, and forecasts for the end of the decade commonly push it past $300 billion. That’s the sort of number that keeps both celebrity founders and growth investors interested.
The consumer behavior behind it is just as important. In the U.S., supplement use is mainstream, not niche, with a large majority of adults reporting that they take some form of supplement. So IM8 doesn’t need to create a market from scratch. It needs to win attention inside a market that already spends heavily.
What’s changed is format and branding. Buyers increasingly want fewer products and easier routines. They also want more personalized-sounding health promises, especially around energy, recovery, gut health, and longevity. A drink-based subscription brand fits that shift better than a wall of disconnected bottles.
There’s also a timing angle here. Longevity has become one of the most commercially useful words in wellness. It’s broad enough to sell aspiration, but specific enough to support premium pricing. That doesn’t mean every longevity-branded product deserves trust. It does mean the category has real consumer pull right now.
The real test for IM8 funding won’t be the size of the headline. It’ll be whether the company can turn Beckham-powered awareness and Yeung’s operating experience into durable subscription retention. If not, it’ll be remembered as a flashy way to prepay for expensive ads.
Read how BiofuelCircle raised a ₹35 crore bridge round led by Spectrum Impact to expand its biomass supply chain platform connecting farmers, aggregators, and industrial buyers across India.
FAQ
- What is the IM8 funding deal?
IM8 secured up to $1 billion from General Catalyst’s Customer Value Fund in a non-equity arrangement. The money is tied to customer acquisition and repayment comes through a capped share of revenue from those customers, not through stock ownership. - How does IM8 work as a product?
IM8 sells a daily wellness drink through a subscription model. Customers sign up for recurring deliveries and use one formula that combines a range of nutrition and longevity-focused ingredients instead of managing separate supplements. - Who founded IM8?
IM8 launched in 2024 with Danny Yeung and David Beckham as a founding partner on the brand side. Yeung had already built Prenetics, the health company that went public in 2022, which gives IM8 a more experienced operating base than a typical celebrity wellness launch. - Is IM8 a supplements brand or a health-tech company?
It’s primarily a consumer supplements brand, but it comes with health-tech DNA because it sits under Prenetics. That mix matters because IM8 isn’t just selling wellness branding. It’s also borrowing credibility from a founder who has already built and listed a health business.
